🇺🇸 FDA
Patent

US 9650444

Anti-PDGFR-beta antibodies and uses thereof

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 9650444 (Anti-PDGFR-beta antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K38/179, A61K39/39541